Artiva shares surge 10.31% premarket after positive AlloNK trial data and FDA Fast Track designation for RA.

Artiva Biotherapeutics surged 10.31% in premarket trading following the release of positive initial safety and translational data for its AlloNK therapy in autoimmune diseases. The company reported that AlloNK, combined with anti-CD20 monoclonal antibodies, achieved deep B-cell depletion in 32 outpatient-treated patients without major adverse events like cytokine release syndrome or graft-versus-host disease. Additionally, the FDA granted Fast Track Designation to AlloNK for refractory rheumatoid arthritis, positioning it as the first therapy in the deep B-cell depletion category to receive such a designation. The data highlights AlloNK’s outpatient feasibility and safety profile, with plans to share clinical response data in 1H 2026 and align on pivotal trial design with the FDA. These developments, coupled with a $123 million cash runway through Q2 2027, fueled investor optimism.